Baseline NT-proBNP predicts acute kidney injury following transcatheter aortic valve implantation.

BACKGROUND/PURPOSE

Acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI) increases morbidity and mortality. Our study aimed to investigate the role of baseline N-terminal pro B-type natriuretic peptide (NT-proBNP) as a predictor of AKI following TAVI.

METHODS

All consecutive TAVI patients were included in the analysis, except patients with dialysis and those with a GFR < 15 ml/min/1.73 m

RESULTS

We included 1973 patients treated with TAVI between January 2006 and December 2016. Median [IQR] age was 81.0 [77.0;84.0] years, the STS score was 6.2 [3.9;9.0], and the logEuroScore was 14.5 [9.0;23.0]. 30-day and one-year mortality was 5.1 % and 16.1 % for all patients, respectively. Multivariate analysis revealed that patients with NT-proBNP levels higher than two times above the upper level of normal (ULN) had an increased risk for AKI after TAVI compared to patients with NT-proBNP levels < 2× ULN (OR 1.40 [1.03-1.91]).

CONCLUSIONS

Routine assessment of baseline NT-proBNP levels might be an additional tool to identify patients at increased risk for AKI after TAVI.

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest Christina Eckrich has no conflict of interest. Sandra Erbs has no conflict of interest. Norman Mangner reports speaker's honoraria from Edwards, Medtronic, Novartis, Sanofi Genzyme, and Astra Zeneca, consultant honoraria from Biotronik, outside the submitted work. Felix Woitek has no conflict of interest. Philipp Kiefer has no conflict of interest. Florian Schlotter has no conflict of interest. Georg Stachel has no conflict of interest. Sergey Leontyev reports personal fees from St. Jude Medical and Medtronic, outside the submitted work. David Holzhey reports personal fees from Symetis and Medtronic, outside the submitted work. Michael A. Borger reports speakers' honoraria and consulting fees from Edwards Lifesciences, Medtronic, and CryoLife, outside the submitted work. Axel Linke reports grants and personal fees from Medtronic, personal fees from St. Jude Medical, grants from Claret Medical, personal fees and other from Claret Medical, personal fees from Boston Scientific, personal fees from Bard, personal fees from Edwards, outside the submitted work. Stephan Haussig reports speakers' honoraria and consulting fees from Edwards Lifesciences, Abbott, Cardiac Dimensions, and Boston Scientific, outside the submitted work